Amphastar Pharmaceuticals/AMPH

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.

Ticker

AMPH

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jack Zhang

Employees

1,761

Headquarters

Rancho cucamonga, United States

AMPH Metrics

BasicAdvanced
$2.1B
Market cap
14.59
P/E ratio
$2.90
EPS
0.82
Beta
-
Dividend rate
$2.1B
0.81844
$67.66
$38.43
370K
2.175
1.723
88.347
88.411
14.525
8.48%
13.33%
25.34%
15.75%
14.589
3.061
3.075
31.704
12.863
30.38%
62.70%
22.58%
349.57%

What the Analysts think about AMPH

Analyst Ratings

Majority rating from 6 analysts.
Buy

AMPH Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
25.08% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$172M
-3.54%
Net income
$43M
19.39%
Profit margin
25.08%
23.79%

AMPH Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 8.65%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.65
$1.15
$0.88
$1.04
-
Expected
$0.56
$0.69
$0.93
$0.96
$0.80
Surprise
16.02%
65.53%
-4.93%
8.65%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Amphastar Pharmaceuticals stock?

Amphastar Pharmaceuticals (AMPH) has a market cap of $2.1B as of June 20, 2024.

What is the P/E ratio for Amphastar Pharmaceuticals stock?

The price to earnings (P/E) ratio for Amphastar Pharmaceuticals (AMPH) stock is 14.59 as of June 20, 2024.

Does Amphastar Pharmaceuticals stock pay dividends?

No, Amphastar Pharmaceuticals (AMPH) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next Amphastar Pharmaceuticals dividend payment date?

Amphastar Pharmaceuticals (AMPH) stock does not pay dividends to its shareholders.

What is the beta indicator for Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (AMPH) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Amphastar Pharmaceuticals stock price target?

The target price for Amphastar Pharmaceuticals (AMPH) stock is $63.25, which is NaN% below the current price of $. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Amphastar Pharmaceuticals stock

Buy or sell Amphastar Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing